For this reason, recent approaches based on DSB-free technologies have been developed to reactivate HbF (by reproducing HPFH mutations55,56,57 or by downregulating the expression of BCL11A, a major HbF transcriptional repressor58) or to revert the SCD-causing mutation.59 This evidence concerns the gene BCL11A and Schnyder corneal dystrophy.